- Research article
- Open Access
- Open Peer Review
Desflurane consumption during automated closed-circuit delivery is higher than when a conventional anesthesia machine is used with a simple vaporizer-O2-N2O fresh gas flow sequence
© De Cooman et al; licensee BioMed Central Ltd. 2008
- Received: 18 April 2008
- Accepted: 17 July 2008
- Published: 17 July 2008
The Zeus® (Dräger, Lübeck, Germany), an automated closed-circuit anesthesia machine, uses high fresh gas flows (FGF) to wash-in the circuit and the lungs, and intermittently flushes the system to remove unwanted N2. We hypothesized this could increase desflurane consumption to such an extent that agent consumption might become higher than with a conventional anesthesia machine (Anesthesia Delivery Unit [ADU®], GE, Helsinki, Finland) used with a previously derived desflurane-O2-N2O administration schedule that allows early FGF reduction.
Thirty-four ASA PS I or II patients undergoing plastic, urologic, or gynecologic surgery received desflurane in O2/N2O. In the ADU group (n = 24), an initial 3 min high FGF of O2 and N2O (2 and 4 L.min-1, respectively) was used, followed by 0.3 L.min-1 O2 + 0.4 L.min-1 N2O. The desflurane vaporizer setting (FD) was 6.5% for the first 15 min, and 5.5% during the next 25 min. In the Zeus group (n = 10), the Zeus® was used in automated closed circuit anesthesia mode with a selected end-expired (FA) desflurane target of 4.6%, and O2/N2O as the carrier gases with a target inspired O2% of 30%. Desflurane FA and consumption during the first 40 min were compared using repeated measures one-way ANOVA.
Age and weight did not differ between the groups (P > 0.05), but patients in the Zeus group were taller (P = 0.04). In the Zeus group, the desflurane FA was lower during the first 3 min (P < 0.05), identical at 4 min (P > 0.05), and slightly higher after 4 min (P < 0.05). Desflurane consumption was higher in the Zeus group at all times, a difference that persisted after correcting for the small difference in FA between the two groups.
Agent consumption with an automated closed-circuit anesthesia machine is higher than with a conventional anesthesia machine when the latter is used with a specific vaporizer-FGF sequence. Agent consumption during automated delivery might be further reduced by optimizing the algorithm(s) that manages the initial FGF or by tolerating some N2 in the circuit to minimize the need for intermittent flushing.
- Anesthesia Machine
- Agent Consumption
- Desflurane Concentration
- Vaporizer Output
Low flow techniques reduce anesthetic agent consumption but are often perceived as cumbersome. First, frequent vaporizer (FD) or fresh gas flow (FGF) adjustments are thought to be needed, especially at the beginning, when initial wash-in and high uptake by the patient rapidly alter the concentrations of anesthetic gases in the circle system. Second, when FGF is lowered below minute ventilation, a discrepancy develops between the delivered and the inspired concentrations of gases and vapors, which has been considered as "lack of control". Finally, the older literature has been preoccupied by the use of rather complex uptake models to administer these agents with closed-circuit anesthesia (CCA) techniques. The administration schedules in the appendix of the monograph by Lowe and Ernst are daunting to the clinician . The Zeus® anesthesia machine (Dräger, Lübeck, Germany) black-boxes these issues for the clinician by administering inhaled agents by automated closed-loop end-expired feedback . However, the Zeus® also has to use a high FGF, initially to wash-in the circuit and the lungs, and later to intermittently flush the circuit to remove unwanted N2. Because this use of high FGF periods increases desflurane consumption above true CCA conditions, we hypothesized that desflurane consumption with a conventional anesthesia machine (ADU® or Anesthesia Delivery Unit, GE, Helsinki, Finland) might be lower than with the Zeus® if used with a previously derived desflurane-O2-N2O FD-FGF schedule that allows very early FGF reduction [3, 4]. The desflurane concentrations resulting from the use of that particular administration schedule with the ADU anesthesia machine have been presented , and in this manuscript we present only those data pertinent to the current study.
After obtaining IRB approval and informed consent, 36 ASA PS I or II patients undergoing plastic, urologic, or gynecologic surgery were enrolled. All patients received oral alprazolam 1 h before the scheduled start of surgery. After preoxygenation (8 L.min-1 O2 FGF for 3 min), propofol (3 mg.kg-1), rocuronium (0.7 mg.kg-1), and sufentanil (0.1 μg.kg-1) were administered intravenously. After intubation of the trachea, ventilation was mechanically controlled. Initial tidal volume and respiratory rate was 500 mL and 10 breaths per minute, respectively; these settings were later adjusted at the discretion of the attending anesthesiologist. Anesthesia was maintained with desflurane in O2-N2O, and additional sufentanil was allowed to be given. Patients were assigned to one of two groups, depending on the anesthesia machine and low flow technique that was used.
In the ADU group (n = 26), an ADU anesthesia machine (Anesthesia Delivery Unit, GE, Helsinki, Finland) was used. Desflurane and O2-N2O were administered with a particular two-step vaporizer-FGF sequence, details of which have been previously described . Briefly, an initial 3 min high FGF of O2 and N2O (2 and 4 L.min-1, respectively) was followed by 0.3 L.min-1 O2 + 0.4 L.min-1 N2O. In patients weighing more than 95 kg, a 4 min high FGF period was used. Desflurane FD was 6.5% for the first 15 min, and 5.5% during the next 25 min. In- and expiratory gases were analyzed by a multigas analyzer (Datex-Ohmeda Compact Airway Module M-CAiOV, Datex-Ohmeda, Helsinki, Finland) and downloaded in a spreadsheet every minute. Gases sampled by the multigas analyzer (200 mL.min-1) were not redirected to the anesthesia circuit to avoid N2 accumulation . In the Zeus group (n = 10), the automated CCA mode was selected with a desflurane FA target of 4.6% and O2-N2O as the carrier gas with an FIO2 target of 30%; 4.5% could not be selected because the desflurane target can only be increased with 0.2% increments. Concentrations of the in- and expiratory gases and agent use were downloaded via the proprietary software in a spreadsheet every minute.
Desflurane consumption with the Zeus® machine was retrieved form the amount of agent the injector has injected into the anesthesia circle system, information that was downloaded to a laptop computer in an Excel file every 10 seconds. With the ADU®, desflurane consumption was first calculated as mL vapor from FGF and vaporizer output (not dialed concentrations); this amount of vapor is easily converted to mL liquid desflurane (1 mL liquid desflurane equals 209.3 mL vapor at 20°C). The same ADU anesthesia machine was used throughout the study. Vaporizer output was intermittently measured at the common gas outlet, and could be related to the dialed concentration as [desflurane vaporizer output (%) = 0.10 + 0.97* vapor setting] – see reference 4 for details.
All results are presented as mean ± standard deviation. Desflurane consumption (retrieved directly from both machines) and desflurane FAduring the first 40 min were compared using repeated measures one-way ANOVA, with P < 0.05 indicating statistical significance.
Age, height, weight, and Body Mass Index (BMI) were 54 ± 12 years, 167 ± 8 cm, 73 ± 12 kg, and 24 ± 6 kg/m2 in the ADU and 51 ± 16 years, 174 ± 9 cm, 73 ± 17 kg, and 24 ± 4 kg/m2 the Zeus group, respectively. Age, weight, and BMI did not differ between the groups (P > 0.05), but patients in the Zeus group were taller (P = 0.04).
Desflurane consumption (cumulative dose, mL liquid) was higher at all times (P < 0.05) during automated closed-circuit anesthesia administration (Zeus®) than with a conventional machine used with the predefined low flow sequence (ADU®).
0.0 ± 0.0
0.0 ± 0.0
6.0 ± 0.0
11.7 ± 4.0
7.1 ± 0.0
12.9 ± 4.1
8.2 ± 0.0
13.9 ± 4.2
9.1 ± 0.2
14.8 ± 4.5
10.0 ± 0.3
15.4 ± 4.3
11.0 ± 0.3
15.9 ± 4.5
11.9 ± 0.3
16.6 ± 4.6
12.8 ± 0.4
17.2 ± 4.8
The use of a specific desflurane-O2-N2O FD-FGF sequence with a conventional anesthesia machine provides comparable end-expired desflurane concentrations and reduces desflurane consumption below that with an automated CCA machine, or alternatively, desflurane consumption during automated closed-circuit delivery is higher than with a conventional anesthesia machine if the latter is used with a particular vaporizer-O2-N2O fresh gas flow sequence.
The performance of the Zeus® has been described in vitro, and compared with the Primus® (Dräger, Lübeck, Germany) . The target desflurane FA was attained slightly later with the Zeus® because part of the fresh gas goes directly to the patient with the Primus®, while fresh gas is extensively mixed in the circle system before reaching the patient in the Zeus® . The ADU® design (with the FGF inflow located just distal to the inspiratory valve) also explains the slightly faster rise of FA desflurane in the ADU group. After wash-in, FA desflurane is maintained within a slightly narrower range with the Zeus® than with the 0.7 L.min-1 FGF with the ADU® (figure 1). More details regarding the performance characteristics of the FD-FGF sequence can be found elsewhere .
Even though it is well known that the initial high FGF period is a major determinant of vapor and gas consumption, many anesthesiologists continue to use high FGF initially because low flow techniques have been perceived as particularly cumbersome to use at the beginning of an anesthetic. Because the initial wash-in and high uptake by the patient rapidly alter the concentrations of anesthetic gases in the circle system, the need for frequent vaporizer and rotameters adjustments required when using low FGF has been claimed to be too distracting at a time when the anesthesiologist is preoccupied by other tasks. Like Lerou , we therefore argue that a simple, clinically easy to apply FD-FGF schedule as used in our ADU group could encourage anesthesiologists to more frequently use lower FGF early on during the anesthetic. With a conventional machine with ascending visible bellows (e.g. the ADU®), the acceptance of a small temporary bellows deficit allows for early FGF reduction (after 3 min), and the small amount of FGF in excess of patient uptake and gas sampling during maintenance slowly washes out N2 yet contributes little to overall desflurane consumption. The somewhat unexpected finding that agent consumption is higher with the Zeus® than with the ADU® is the result of two factors: the use of a very high initial FGF (> 11 L/min) and the intermittent flushing of the gas reservoir when N2 concentration reaches a certain threshold. The effect of the first factor is readily demonstrated by calculating the effect on desflurane consumption of shortening the high FGF period by one min. With the described FD-FGF sequence with the ADU®, desflurane consumption is 12.8 mL after 40 min; when the duration of high FGF is extended by one min, total consumption increases to 14.4 mL. If the high FGF would be extended by another 2 minutes, desflurane consumption would become similar to that with the Zeus®. The second important factor that explains the difference in agent consumption is the difference in the manner the two techniques handle N2. With the conventional anesthesia machine, gases sampled by the agent analyzer (200 mL.min-1) are not redirected to the anesthesia circuit (avoiding air entrainment by the gas analyzer into the circuit at a rate of 32 m L.min-1 ), and the 0.7 L.min-1 maintenance FGF used with the FD-FGF sequence therefore ensures that N2 concentration in the circuit remains very low and even continues to decrease despite a relatively short high FGF period (figure 2). The Zeus® takes a different approach. As soon as possible and whenever possible, it will try to convert to CCA conditions. Closing the circuit will inevitable lead to a subsequent increase in N2 in the anesthesia circuit because vessel rich tissues are still releasing significant amounts of N2. Whenever the FIN2 increases above a certain threshold (e.g. FIN2 of 15%), FGF is increased to flush the circuit (figure 3). Our data indicate that serial flushing to reduce N2 increases agent consumption well above the amount taken up by the patient, to the extent that desflurane consumption with our current FD-FGF sequence used with a conventional anesthesia machine and a FGF in between minimal flow (0.5 L.min-1) and low flow (1.0 L.min-1) becomes lower than that with an automated closed-circuit anesthesia machine, that – according to the definition of closed circuit anesthesia – should administer just that amount of agent that is taken up by the patient and lost via circuit leaks. This suggests that administration regimens similar to ours could help steer more conventional anesthesia machines to lower agent consumption similar to or below that of automated closed-loop feedback anesthesia machines, or could be used to optimize administration algorithms of automated closed-loop feedback anesthesia machines themselves. Agent consumption by the Zeus® could be further reduced by optimizing the algorithm that manages the initial FGF (e.g. by allowing a more gradual rise towards the desired anesthetic gas concentrations) or by tolerating some N2 in the circuit to minimize the need for high FGF used during intermittent flushing. Our findings also suggest that the actual FGFs used by a particular technique or device should always be explicitly mentioned to allow proper interpretation of terms like "closed-circuit".
Anesthetic agent consumption with an automated closed-circuit anesthesia machine is higher than with a conventional anesthesia machine if the latter is used with a specific vaporizer-FGF sequence. More specifically, one desflurane vaporizer and one O2/N2O FGF change with a conventional anesthesia machine with ascending visible bellows suffices to maintain satisfactory anesthetic gas concentrations within a clinically sufficiently narrow range during the first 20–30 min in most patients. The higher consumption with the closed-circuit anesthesia machine is caused by the use of high FGF for initial circuit and lung wash-in and by intermittent flushing of the circuit to reduce N2 accumulation. We therefore suggest that agent consumption during automated delivery can be further reduced by optimizing the algorithm(s) that manages the initial FGF (e.g. by allowing a more gradual rise towards the desired anesthetic gas concentrations) or by tolerating some N2 in the circuit to minimize the need for intermittent flushing.
- Lowe J, Ernst E: The quantitative practice of anesthesia – use of a closed circuit. 1981, Baltimore: Williams & WilkinsGoogle Scholar
- Struys MMRF, Kalmar AF, De Baerdemaeker LEC, Mortier EP, Rolly G, Manigel J, Buschke W: Time course of inhaled anaesthetic drug delivery using multifunctional closed-circuit anaesthesia ventilator. In vitro comparison with a classical anaesthesia machine. Br J Anaesth. 2005, 94: 306-317. 10.1093/bja/aei051.View ArticlePubMedGoogle Scholar
- Hendrickx JFA, Cardinael S, Carette R, Lemmens HJ, De Wolf AM: The Ideal O2/N2O Fresh Gas Flow (FGF) Sequence with the Anesthesia Delivery Unit Machine. J Clin Anesth. 2007, 19: 274-279. 10.1016/j.jclinane.2007.01.003.View ArticlePubMedGoogle Scholar
- Hendrickx JFA, Dewulf BBC, De Mey N, Carette R, Deloof T, De Cooman S, De Wolf AM: Development and performance of a two step desflurane – O2/N2O fresh gas flow sequence. J Clin Anesth. Google Scholar
- Hendrickx JFA, Van Zundert AAJ, De Wolf AM: Influence of the reference gas of paramagnetic oxygen analyzers on nitrogen concentrations during closed-circuit anesthesia. J Clin Monit Comp. 1998, 14: 381-84. 10.1023/A:1009969219569.View ArticleGoogle Scholar
- Lerou JG, Verheijen R, Booij LH: Model-based administration of inhalation anaesthesia. 4. Applying the system model. Br J Anaesth. 2002, 88: 175-83. 10.1093/bja/88.2.175.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2253/8/4/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.